Form 8-K - Current report:
SEC Accession No. 0000950170-23-024920
Filing Date
2023-05-30
Accepted
2023-05-30 16:51:31
Documents
14
Period of Report
2023-05-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tals-20230526.htm   iXBRL 8-K 66264
2 EX-99.1 tals-ex99_1.htm EX-99.1 15340
3 GRAPHIC img186005553_0.jpg GRAPHIC 9383
  Complete submission text file 0000950170-23-024920.txt   217101

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20230526_lab.xml EX-101.LAB 13350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20230526_pre.xml EX-101.PRE 9834
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20230526.xsd EX-101.SCH 2460
8 EXTRACTED XBRL INSTANCE DOCUMENT tals-20230526_htm.xml XML 4703
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 23977298
SIC: 2836 Biological Products, (No Diagnostic Substances)